- Home
- OMER
OMER
Omeros Corporation
as 03-31-2025 11:43am EST
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | N/A | IPO Year: | 2009 |
| Target Price: | $22.50 | AVG Volume (30 days): | 501.2K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.61 - $13.60 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Omeros Corporation News
OMER Breaking Stock News: Dive into OMER Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
Clinical Trials Arena
7 days ago
Omeros to activate site for Phase III programme of zaltenibart for PNH
MT Newswires
10 days ago
Omeros Says Trial Site Activation Underway for Phase 3 Study of Zaltenibart
Business Wire
10 days ago
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
Business Wire
18 days ago
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
TipRanks
a month ago
Omeros announces results for narsoplimab expanded access program
Business Wire
a month ago
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Business Wire
a month ago
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
Compare OMER vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMER Omeros Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.